Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject must have successfully completed either the M02-404 (NCT00077779) or M04-691 (NCT00105300) protocol to be eligible for this study~* Diagnosis of Crohn's disease~* Willing and able to give informed consent~Exclusion Criteria:~* Diagnosis of ulcerative colitis~* Women cannot be pregnant or breastfeeding~* Previous history of listeria infection or untreated tuberculosis~* Previous history of cancer other than successfully treated skin cancer or carcinoma-in-situ of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).